Published in J Neurol Neurosurg Psychiatry on January 01, 1996
Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry (2003) 1.15
Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry (1999) 1.14
Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups. J Neurol Neurosurg Psychiatry (1998) 1.03
One year follow up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2000) 0.99
Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx (2005) 0.98
Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (2002) 0.98
Is inflammation important in early PPMS? a longitudinal MRI study. J Neurol Neurosurg Psychiatry (2005) 0.95
Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. Philos Trans R Soc Lond B Biol Sci (1999) 0.94
Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol (2005) 0.89
More immunotherapy for multiple sclerosis. J Neurol Neurosurg Psychiatry (1996) 0.88
Neurological rehabilitation: from mechanisms to management. J Neurol Neurosurg Psychiatry (2000) 0.82
Advanced imaging of the cervical spine and spinal cord in 22q11.2 deletion syndrome: age-matched, double-cohort, controlled study. J Child Orthop (2008) 0.81
Progressive multiple sclerosis and gray matter pathology: an MRI perspective. Mt Sinai J Med (2011) 0.81
Neuroradiological evaluation of demyelinating disease. Ther Adv Neurol Disord (2013) 0.80
Axial 3D gradient-echo imaging for improved multiple sclerosis lesion detection in the cervical spinal cord at 3T. Neuroradiology (2012) 0.79
Imaging as an Outcome Measure in Multiple Sclerosis. Neurotherapeutics (2016) 0.79
Multiple sclerosis: Lesion location may predict disability in multiple sclerosis. Nat Rev Neurol (2010) 0.78
Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis. Philos Trans R Soc Lond B Biol Sci (1999) 0.77
Gut dysfunction in patients with multiple sclerosis and the role of spinal cord involvement in the disease. Eur J Gastroenterol Hepatol (2013) 0.77
Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study. J Neurol Neurosurg Psychiatry (2003) 0.76
Cervical spinal cord dimensions and clinical outcomes in adults with klippel-feil syndrome: a comparison with matched controls. Global Spine J (2014) 0.75
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Ther Adv Neurol Disord (2016) 0.75
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 40.64
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol (1991) 2.25
Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology (1993) 1.87
A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain (1994) 1.53
The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol (1992) 1.52
Spinal cord MRI using multi-array coils and fast spin echo. I. Technical aspects and findings in healthy adults. Neurology (1993) 1.00
Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta. Ann Neurol (1994) 0.90
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci (2003) 10.44
Delayed visual evoked response in optic neuritis. Lancet (1972) 6.11
Visual evoked response in diagnosis of multiple sclerosis. Br Med J (1973) 5.61
Diagnosis and classification of multiple sclerosis. Br Med Bull (1977) 4.68
Hydroxyproline arabinosides in the plant kingdom. Plant Physiol (1971) 4.67
Oral contraceptives and cerebral arterial occlusion. Br Med J (1965) 4.42
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology (2003) 3.75
Neural correlates of motor recovery after stroke: a longitudinal fMRI study. Brain (2003) 3.65
Detection and modeling of non-Gaussian apparent diffusion coefficient profiles in human brain data. Magn Reson Med (2002) 3.53
The effects of experimental demyelination on conduction in the central nervous system. Brain (1970) 3.31
Genetic heterogeneity and mitochondrial DNA heteroplasmy in Leber's hereditary optic neuropathy. J Med Genet (1989) 3.25
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
Neural correlates of outcome after stroke: a cross-sectional fMRI study. Brain (2003) 3.04
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain (2000) 2.84
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
The stochastic nature of larval connectivity among nearshore marine populations. Proc Natl Acad Sci U S A (2008) 2.65
Technique for measuring hippocampal T2 relaxation time. AJNR Am J Neuroradiol (1997) 2.65
Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol (1984) 2.64
Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain (1992) 2.62
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol (1993) 2.56
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain (1990) 2.53
Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol (1985) 2.50
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44
The persistent vegetative state. BMJ (1995) 2.35
Management of acute optic neuritis. Lancet (2002) 2.33
Parathyroid venous sampling: anatomic considerations and results in 95 patients with primary hyperparathyroidism. Br J Radiol (1980) 2.29
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain (1988) 2.29
Estimating individual contributions to population growth: evolutionary fitness in ecological time. Proc Biol Sci (2006) 2.25
Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol (1991) 2.25
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Factors influencing the risk of multiple sclerosis developing in patients with optic neuritis. Brain (1978) 2.19
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Test liquids for quantitative MRI measurements of self-diffusion coefficient in vivo. Magn Reson Med (2000) 2.14
Hydroxyproline heterooligosaccharides in Chlamydomonas. Science (1972) 2.12
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11
The pattern-evoked potential in compression of the anterior visual pathways. Brain (1976) 2.07
The clinical picture of ectasia of the intracerebral arteries. J Neurol Neurosurg Psychiatry (1982) 2.05
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
PAX6 haploinsufficiency causes cerebral malformation and olfactory dysfunction in humans. Nat Genet (2001) 2.05
The Functional Independence Measure: a comparative validity and reliability study. Disabil Rehabil (1995) 2.04
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry (2000) 2.01
Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 2.01
Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain (1990) 2.00
Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain (1989) 2.00
Immunologic studies in IgA nephropathy. Kidney Int (1980) 1.99
Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ (1990) 1.99
Striking a balance between biodiversity conservation and socioeconomic viability in the design of marine protected areas. Conserv Biol (2008) 1.99
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain (1998) 1.99
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry (2005) 1.97
The chemical composition of the cell wall of Chlamydomonas gymnogama and the concept of a plant cell wall protein. J Cell Biol (1974) 1.95
Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. Ann Neurol (1987) 1.93
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology (2009) 1.93
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
EEG-triggered functional MRI of interictal epileptiform activity in patients with partial seizures. Brain (1999) 1.88
Spinal epidural angiomatous malformations draining into intrathecal veins. Neuroradiology (1977) 1.88
Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology (1993) 1.87
Habitat structure and population persistence in an experimental community. Nature (2001) 1.86